Bengaluru-based Ayati Devices has secured Rs 15 crore in a pre-Series A funding round led by Inflexor Ventures. The company, which specializes in diagnostic tools for diabetic complications, will use the capital to boost manufacturing and AI research. As a private entity, the focus remains on scaling its global footprint and maintaining regulatory compliance in the medical device sector.
Ayati Devices, a Bengaluru-based medical technology startup, has raised Rs 15 crore in a pre-Series A funding round. The investment, led by Inflexor Ventures, is intended to support the company’s efforts to increase its manufacturing capacity and accelerate the commercial rollout of its diagnostic platforms in both Indian and international markets.
Founded in 2019 and incubated at IIT Bombay’s Society for Innovation and Entrepreneurship, the company develops portable, point-of-care diagnostic equipment. Its core portfolio includes devices such as Vibrasense, Vasosense, and Angiocam, which are designed to assist medical professionals in identifying diabetic foot complications and vascular conditions. These technologies are often used in primary care clinics and hospitals to provide screenings that traditionally required specialized facilities.
With over 10,000 units already deployed across 30 countries, Ayati Devices has emphasized compliance with global quality standards. The company holds certifications from the Central Drugs Standard Control Organisation in India, as well as the US FDA and CE certification for European markets. The latest funding is expected to help the company enhance its research into artificial intelligence, particularly in creating clinical decision-support systems that analyze diagnostic data to help predict ulcer development or manage patient follow-ups.
For observers of the medical device sector, the growth path for such companies is closely tied to operational execution. Scaling manufacturing while maintaining strict global regulatory standards involves significant capital and technical effort. Additionally, the company operates in a specialized market where clinical adoption by hospitals and clinics is essential for long-term growth. Because Ayati Devices is a private company, it does not trade on public stock exchanges like the NSE or BSE, meaning its performance is not tracked through daily share price movements but rather through its ability to scale product adoption and maintain financial stability.
The next important monitorables for the company will involve proving the efficacy of its AI-enhanced diagnostic tools in real-world clinical settings and managing the complexities of international supply chains. Future growth will likely depend on the company's ability to sustain demand for its diagnostic platform and navigate the operational challenges inherent in the highly regulated medical device industry.